Untitled

Sunil Arvindam, Upasana
2022-05
Thumbnail Image

View/Download File

SunilArvindam_umn_0130E_23236.pdf (3.41 MB)

Persistent link to this item

https://hdl.handle.net/11299/241324
Statistics
View Statistics

Journal Title

Journal ISSN

Volume Title

Title

Authors

Published Date

2022-05

Publisher

Type

Thesis or Dissertation

Abstract

Natural Killer (NK) cells are cytotoxic innate immune cells that are important components of anti-tumor immunity. They make up 5-15% of total lymphocytes and are derived from the common lymphoid progenitor. Their phenotype is determined by the marker CD56 that divides them into two groups, CD56bright and CD56dim cells. CD56bright cells have a lower cytotoxic capacity but show high proliferation and cytokine secretion upon stimulation. CD56dim cells display high cytotoxic capacity. NK cells can recognize and killer tumor cells through a wide array of germline encoded receptors. They can facilitate broader immune system activation through the secretion of pro-inflammatory cytokines. NK cell-based treatments can be divided into two main areas; biologics that enhance endogenous NK cell function and adoptive transfer of NK cells. Both these treatments are being developed to increase targeting of therapeutic NK cells towards tumor cells. We have established a series of NK cell biologics called trispecific killer engagers (TriKETM). To target acute myeloid leukemia (AML) cells, we developed a TriKE containing an anti-CD16 portion that activates NK cells, an IL-15 molecule that drives NK cell priming, expansion and survival, and a portion against the AML antigen, CLEC12A (CLEC12A TriKE). The CLEC12A TriKE induced robust NK cell proliferation, enhanced killing of both AML cell lines and primary patient derived AML blasts and reduced tumor burden in pre-clinical mouse models. For TriKE based treatments to be successful in solid tumors, we need to address the additional mechanisms of immune suppression that exist in the solid tumor microenvironment (TME). We focused on the role of low oxygen or hypoxia (1% O2) on NK cell function and found that hypoxia strongly inhibits NK cell proliferation and cytotoxicity. There is a decrease in the expression of activating receptors, cytotoxicity markers and key transcription factors (Tbet and Eomes). There is change in NK cell metabolism with a switch to glycolysis. Hypoxia results in a remodeling of the transcriptome and epigenome. We investigated the impact of exogenous therapeutics on NK cells under hypoxia with the addition of recombinant IL-15 or TriKE and the use of NK cells that have been expanded on K562 feeder cells containing 4-1BBL and IL-21. These therapeutics improved NK cell killing under hypoxia. Future directions include combination therapies with biologics and adoptive transfer of genetically modified NK cells that function better in suppressive TMEs.

Keywords

Description

University of Minnesota Ph.D. dissertation. May 2022. Major: Microbiology, Immunology and Cancer Biology. Advisor: Jeffrey Miller. 1 computer file (PDF); viii, 120 pages.

Related to

Replaces

License

Collections

Dissertations

Series/Report Number

Funding information

Isbn identifier

Doi identifier

Previously Published Citation

Other identifiers

Suggested citation

Sunil Arvindam, Upasana. (2022). untitled - dbId: f771d9d3-ac67-4446-bd1a-0d9838d052f9. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/241324.

Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.